Skip to content
aSSIST Business Review aSSIST Business Review aSSIST Business Review aSSIST Business Review
Home

Article

Transforming Obesity Management: Integrating AI-Driven Digital Health and Novel Pharmacotherapy

Kang, Eun Kyoung , Kim, Bo Young Primary Contact Corresponding Author
PDF
Abstract

The global obesity epidemic presents a critical public health and economic challenge, requiring innovative, integrated solutions. (1) Background/Purpose: This study explores advanced strategies for obesity management, focusing on the integration of AI-driven digital health platforms and next-generation pharmacotherapy, using the Technology-Organization-Environment (TOE) framework. Two industry leaders are examined: Noom, known for its AI-powered behavioral coaching platform, and Novo Nordisk, a pioneer in GLP-1 receptor agonist-based pharmacological treatment (Wegovy/semaglutide). (2) Methodology/Approach: A multi-layered qualitative case study methodology was employed, incorporating document analysis of corporate financial reports, investor presentations, and official press releases; a systematic literature review from PubMed, ScienceDirect, and The Lancet; regulatory filings from the FDA, EMA, and WHO; and comparative data extraction. The TOE framework structured analysis across technological, organizational, and environmental dimensions for both companies. (3) Findings: Both companies demonstrate that ecosystem integration—combining digital coaching with pharmacotherapy—substantially enhances obesity management outcomes. Noom achieves 5–7% average body weight reduction through AI-driven behavioral coaching and strategic partnerships, while Wegovy achieves 14.9% average weight reduction over 68 weeks (STEP 1 trial), with additional 20% cardiovascular risk reduction (SELECT trial). The joint integration of behavioral health tools and pharmacotherapy offers a hybrid approach addressing both biological mechanisms and lifestyle-related behaviors. Key challenges include high treatment costs, patient adherence barriers, and complex regulatory frameworks. (4) Originality/Value: This study provides actionable insights into emerging business models and collaborative opportunities that leverage digital innovation and pharmacological advancements, emphasizing the potential for personalized, technology-driven care to transform obesity management. Future research should focus on integrating multi-omics data, advancing precision medicine, and exploring innovative healthcare delivery models.

References
  1. Adams, T. D., Gress, R. E., Smith, S. C., Halverson, R. C., Simper, S. C., Rosamond, W. D., Lamonte, M. J., Stroup, A. M., & Hunt, S. C. (2007). Long-term mortality after gastric bypass surgery. N Engl J Med, 357(8), 753–761. https://doi.org/10.1056/NEJMoa066603
  2. Ahmed Aboulenein, P. W. (2024). Wegovy to be covered by US Medicare for heart disease patients. Reuters. https://www.reuters.com/business/healthcare-pharmaceuticals/wegovy-be-covered-by-us-medicare-heart-disease-patients-2024-03-21/
  3. Altimmune Presents Data from Phase 2 MOMENTUM Trial of Pemvidutide in Obesity during Oral Presentation at the American Diabetes Association's 84th Scientific Sessions. (2024). Altimmune. https://ir.altimmune.com/news-releases/news-release-details/altimmune-presents-data-phase-2-momentum-trial-pemvidutide
  4. Amaro, A., Sugimoto, D., & Wharton, S. (2022). Efficacy and safety of semaglutide for weight management: evidence from the STEP program. Postgrad Med, 134(sup1), 5–17. https://doi.org/10.1080/00325481.2022.2147326
  5. Anderson, J., Kushner, R., Miller, E., Nadglowski, J., & Still, C. (2022). Overweight and Obesity Management for Primary Care Clinicians: Executive Summary. Clin Diabetes, 41(1), 85–89. https://doi.org/10.2337/cd22-0082
  6. Annual Report 2023. Novo Nordisk. https://www.novonordisk.com/investors/annual-report.html
  7. Apps Noom Syncs With On Android. Noom. https://www.noom.com/support/faqs/question-topics/sync-apps-devices/2016/12/apps-noom-syncs-with-on-android/
  8. The Art of Invisible Learning: How We Built and Scaled L&D From Ground Zero in a Startup. 360learning. https://360learning.com/blog/the-art-of-invisible-learning-scaling-l-and-d/
  9. Arterburn, D. E., Telem, D. A., Kushner, R. F., & Courcoulas, A. P. (2020). Benefits and Risks of Bariatric Surgery in Adults: A Review. JAMA, 324(9), 879–887. https://doi.org/10.1001/jama.2020.12567
  10. Bergmann, N. C., Davies, M. J., Lingvay, I., & Knop, F. K. (2023). Semaglutide for the treatment of overweight and obesity: A review. Diabetes Obes Metab, 25(1), 18–35. https://doi.org/10.1111/dom.14863
  11. Biggs, J. (2021). What are 'personalised' diet apps like Noom really doing with our data? Cosmopolitan. https://www.cosmopolitan.com/uk/body/diet-nutrition/a37635743/noom-review/
  12. Bliddal, H., & Christensen, R. (2006). The management of osteoarthritis in the obese patient: practical considerations and guidelines for therapy. Obes Rev, 7(4), 323–331. https://doi.org/10.1111/j.1467-789X.2006.00252.x
  13. Brandfon, S., Eylon, A., Khanna, D., & Parmar, M. S. (2023). Advances in Anti-obesity Pharmacotherapy: Current Treatments, Emerging Therapies, and Challenges. Cureus, 15(10), e46623. https://doi.org/10.7759/cureus.46623
  14. Bray, G. A., Kim, K. K., Wilding, J. P. H., & World Obesity Federation. (2017). Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obes Rev, 18(7), 715–723. https://doi.org/10.1111/obr.12551
  15. Caffrey, M. (2017). Digital Health Provider Noom Wins Full CDC Recognition for Mobile, Online Applications. AJMC. https://www.ajmc.com/view/digital-health-provider-noom-wins-full-cdc-recognition-for-mobile-online-applications
  16. Chapter 1. The economic impacts of the COVID-19 crisis. (2022). World Bank Group. https://www.worldbank.org/en/publication/wdr2022/brief/chapter-1-introduction-the-economic-impacts-of-the-covid-19-crisis
  17. Cifuentes, L., Hurtado, A. M., Eckel-Passow, J., & Acosta, A. (2021). Precision Medicine for Obesity. Dig Dis Interv, 5(3), 239–248. https://doi.org/10.1055/s-0041-1729945
  18. Comstock, J. (2012). Fitness app-maker Noom nabs $2.6M for Korean expansion. MobiHealthNews. https://www.mobihealthnews.com/19654/fitness-app-maker-noom-nabs-2-6m-for-korean-expansion
  19. Covered Entities vs Non-Covered Entities under HIPAA. (2024). Medomic. https://www.metomic.io/resource-centre/covered-entities-v-non-covered-entities
  20. De Luca, M., Shikora, S., Eisenberg, D., Angrisani, L., Parmar, C., et al. (2024). Scientific evidence for the updated guidelines on indications for metabolic and bariatric surgery (IFSO/ASMBS). Surg Obes Relat Dis, 20(11), 991–1025. https://doi.org/10.1016/j.soard.2024.05.009
  21. Deanfield, J., Verma, S., Scirica, B. M., Kahn, S. E., Emerson, S. S., et al. (2024). Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. Lancet, 404(10454), 773–786. https://doi.org/10.1016/S0140-6736(24)01498-3
  22. Digital Health Trends 2024, Implications for Research and Patient Care. (2024). IQVIA. https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/digital-health-trends-2024
  23. Digital partnerships & solutions. Novo Nordisk. https://www.novonordisk.com/partnering-and-open-innovation/digital-partnerships-and-solutions.html
  24. Donnelly, J. E., Blair, S. N., Jakicic, J. M., Manore, M. M., Rankin, J. W., Smith, B. K., & American College of Sports Medicine. (2009). ACSM Position Stand: Physical activity intervention strategies for weight loss and prevention of weight regain for adults. Med Sci Sports Exerc, 41(2), 459–471. https://doi.org/10.1249/MSS.0b013e3181949333
  25. Economic impact of overweight and obesity to surpass $4 trillion by 2035. (2023). World Obesity Federation. https://www.worldobesity.org/news/economic-impact-of-overweight-and-obesity-to-surpass-4-trillion-by-2035
  26. Economic impacts of overweight and obesity: current and future estimates for eight countries. (2021). BMJ Global Health. https://gh.bmj.com/content/6/10/e006351
  27. Elmaleh-Sachs, A., Schwartz, J. L., Bramante, C. T., Nicklas, J. M., Gudzune, K. A., & Jay, M. (2023). Obesity Management in Adults: A Review. JAMA, 330(20), 2000–2015. https://doi.org/10.1001/jama.2023.19897
  28. Esch, K. (2023). What's Included in an Employee Weight Management Program? Marathon Health. https://marathon.health/blog/employee-weight-management-program
  29. FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight. (2024). U.S. Food & Drug Administration. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or
  30. FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014. (2021). U.S. Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-chronic-weight-management-first-2014
  31. Felson, D. T., Zhang, Y., Hannan, M. T., Naimark, A., Weissman, B., Aliabadi, P., & Levy, D. (1997). Risk factors for incident radiographic knee osteoarthritis in the elderly: the Framingham Study. Arthritis Rheum, 40(4), 728–733. https://doi.org/10.1002/art.1780400420
  32. Fernando, M. (2024). Study compares Mounjaro to Wegovy for weight loss. NewsGP. https://www1.racgp.org.au/newsgp/clinical/study-compares-mounjaro-to-wegovy-for-weight-loss
  33. Fountzilas, E., Tsimberidou, A. M., Vo, H. H., & Kurzrock, R. (2022). Clinical trial design in the era of precision medicine. Genome Med, 14(1), 101. https://doi.org/10.1186/s13073-022-01102-1
  34. Gardner, J. (2024). Drugmakers are racing to find the next Wegovy. These obesity trials are ones to watch. Yahoo! Finance. https://finance.yahoo.com/news/drugmakers-racing-next-wegovy-obesity-094900280.html
  35. Garvey, W. T., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med, 28(10), 2083–2091. https://doi.org/10.1038/s41591-022-02026-4
  36. Geoff Cook Joins Noom as Chief Executive Officer. (2023). Businesswire. https://www.businesswire.com/news/home/20230718063387/en/Geoff-Cook-Joins-Noom-as-Chief-Executive-Officer
  37. Ghusn, W., De la Rosa, A., Sacoto, D., Cifuentes, L., Campos, A., Feris, F., Hurtado, M. D., & Acosta, A. (2022). Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity. JAMA Netw Open, 5(9), e2231982. https://doi.org/10.1001/jamanetworkopen.2022.31982
  38. Global Obesity Report 2022. (2022). World Obesity Federation. https://www.worldobesity.org/resources/resource-library/world-obesity-atlas-2022
  39. Growth Strategy and Future Prospects of Noom. (2024). Canvas Business Model. https://canvasbusinessmodel.com/blogs/growth-strategy/noom-growth-strategy
  40. Grunvald, E., Shah, R., Hernaez, R., Chandar, A. K., Pickett-Blakely, O., et al. (2022). AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity. Gastroenterology, 163(5), 1198–1225. https://doi.org/10.1053/j.gastro.2022.08.045
  41. Hasin, Y., Seldin, M., & Lusis, A. (2017). Multi-omics approaches to disease. Genome Biol, 18(1), 83. https://doi.org/10.1186/s13059-017-1215-1
  42. The health project. IBM. https://thehealthproject.com/winner/wellness-for-life-international-business-machines/
  43. The Heavy Burden of Obesity: The Economics of Prevention. (2019). OECD. https://www.oecd.org/en/publications/the-heavy-burden-of-obesity_67450d67-en.html
  44. Heymsfield, S. B., & Wadden, T. A. (2017). Mechanisms, Pathophysiology, and Management of Obesity. N Engl J Med, 376(15), 1492. https://doi.org/10.1056/NEJMc1701944
  45. Jae-won, K. (2015). Allianz launches healthcare app. The Korea Times. https://www.koreatimes.co.kr/www/biz/2024/12/602_181979.html
  46. Jakicic, J. M., & Otto, A. D. (2006). Treatment and prevention of obesity: what is the role of exercise? Nutr Rev, 64(2 Pt 2), S57–61. https://doi.org/10.1111/j.1753-4887.2006.tb00235.x
  47. Johnston, B. C., Kanters, S., Bandayrel, K., Wu, P., Naji, F., et al. (2014). Comparison of weight loss among named diet programs in overweight and obese adults: a meta-analysis. JAMA, 312(9), 923–933. https://doi.org/10.1001/jama.2014.10397
  48. Khera, R., Murad, M. H., Chandar, A. K., Dulai, P. S., Wang, Z., et al. (2016). Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis. JAMA, 315(22), 2424–2434. https://doi.org/10.1001/jama.2016.7602
  49. Kim, H. H., Kim, Y., Michaelides, A., & Park, Y. R. (2022). Weight Loss Trajectories and Related Factors in a 16-Week Mobile Obesity Intervention Program: Retrospective Observational Study. J Med Internet Res, 24(4), e29380. https://doi.org/10.2196/29380
  50. Kopelman, P. G. (2000). Obesity as a medical problem. Nature, 404(6778), 635–643. https://doi.org/10.1038/35007508
  51. Kozak, A. T., Buscemi, J., Hawkins, M. A., Wang, M. L., Breland, J. Y., Ross, K. M., & Kommu, A. (2017). Technology-based interventions for weight management: current randomized controlled trial evidence and future directions. J Behav Med, 40(1), 99–111. https://doi.org/10.1007/s10865-016-9805-z
  52. Lavie, C. J., Milani, R. V., & Ventura, H. O. (2009). Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol, 53(21), 1925–1932. https://doi.org/10.1016/j.jacc.2008.12.068
  53. Lee, Y., Lee, N. Y., Lim, H. J., & Sung, S. (2022). Weight Reduction Interventions Using Digital Health for Employees with Obesity: A Systematic Review. Diabetes Metab Syndr Obes, 15, 3121–3131. https://doi.org/10.2147/DMSO.S384450
  54. Lilly's Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs. 13.7%. (2024). PR Newswire. https://www.prnewswire.com/news-releases/lillys-zepbound-tirzepatide-superior-to-wegovy-semaglutide-in-head-to-head-trial-showing-an-average-weight-loss-of-20-2-vs-13-7-302322351.html
  55. Ling, C., & Ronn, T. (2019). Epigenetics in Human Obesity and Type 2 Diabetes. Cell Metab, 29(5), 1028–1044. https://doi.org/10.1016/j.cmet.2019.03.009
  56. Lingvay, I., Sumithran, P., Cohen, R. V., & le Roux, C. W. (2022). Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. The Lancet, 399(10322), 394–405. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01919-X/abstract
  57. Locke, A. E., Kahali, B., Berndt, S. I., Justice, A. E., Pers, T. H., et al. (2015). Genetic studies of body mass index yield new insights for obesity biology. Nature, 518(7538), 197–206. https://doi.org/10.1038/nature14177
  58. Mahapatra, M. K., Karuppasamy, M., & Sahoo, B. M. (2022). Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes. Rev Endocr Metab Disord, 23(3), 521–539. https://doi.org/10.1007/s11154-021-09699-1
  59. May, C. N., Cox-Martin, M., Ho, A. S., McCallum, M., Chan, C., et al. (2023). Weight loss maintenance after a digital commercial behavior change program (Noom Weight): Observational cross-sectional survey study. Obes Sci Pract, 9(5), 443–451. https://doi.org/10.1002/osp4.666
  60. Meet four women using apps and games to drive culture and create change. (2023). Apple Newsroom. https://www.apple.com/newsroom/2023/03/meet-four-women-using-apps-and-games-to-drive-culture-and-create-change/
  61. Milne-Ives, M., Burns, L., Swancutt, D., Calitri, R., Ananthakrishnan, A., Davis, H., Pinkney, J., Tarrant, M., & Meinert, E. (2024). The effectiveness and usability of online, group-based interventions for people with severe obesity: a systematic review and meta-analysis. Int J Obes (Lond). https://doi.org/10.1038/s41366-024-01669-2
  62. Mingrone, G., Panunzi, S., De Gaetano, A., Guidone, C., Iaconelli, A., et al. (2021). Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial. Lancet, 397(10271), 293–304. https://doi.org/10.1016/S0140-6736(20)32649-0
  63. Mitchell, E. S., Fabry, A., Ho, A. S., May, C. N., Baldwin, M., et al. (2023). The Impact of a Digital Weight Loss Intervention on Health Care Resource Utilization and Costs Compared Between Users and Nonusers With Overweight and Obesity: Retrospective Analysis Study. JMIR Mhealth Uhealth, 11, e47473. https://doi.org/10.2196/47473
  64. A New Use for Wegovy Opens the Door to Medicare Coverage for Millions of People with Obesity. (2024). KFF. https://www.kff.org/medicare/issue-brief/a-new-use-for-wegovy-opens-the-door-to-medicare-coverage-for-millions-of-people-with-obesity/
  65. Noom. (2024). Wikipedia. https://en.wikipedia.org/wiki/Noom
  66. Noom + Fitbit: How to Sync Them Together. (2022). prettysweet. https://prettysweet.com/noom-fitbit-sync/
  67. Noom grows revenue by 80% through localization on Google Play! Google Play. https://play.google.com/console/about/noom-casestudy/
  68. Noom Introduces AI-Enabled Products to Enhance On-Demand Health Care and Interactive Coaching. (2024). Noom. https://www.noom.com/in-the-news/noom-introduces-ai-enabled-products-to-enhance-on-demand-health-care-and-interactive-coaching-2/
  69. Noom Introduces Innovative In-App Body Scan Technology to Monitor Muscle-Mass Retention During GLP-1 Treatment. (2024). Noom. https://www.noom.com/in-the-news/noom-introduces-innovative-in-app-body-scan-technology-to-monitor-muscle-mass-retention-during-glp-1-treatment/
  70. Noom marketing mix. Canvas Business Model. https://canvasbusinessmodel.com/products/noom-marketing-mix
  71. Noom Pestel Analysis. Canvas Business Model. https://canvasbusinessmodel.com/products/noom-pestle-analysis
  72. Noom Revenue and Usage Statistics. (2023). Mobile Marketing Reads. https://mobilemarketingreads.com/noom-revenue-and-usage-statistics-2021/
  73. Noom Weight Loss Success: How Celebrities Slim Down with Noom. Irelandgolf. https://irelandgolf.com/news/en-noom-weight-loss-success-how-celebrities-slim-down-with-noom-ef74365.html
  74. Nordisk, N. (2023). Novo Nordisk R&D Report. https://ec.europa.eu/health/documents/community-register/2023/20230331158642/anx_158642_en.pdf
  75. Nordmann, A. J., Nordmann, A., Briel, M., Keller, U., Yancy, W. S., Jr., Brehm, B. J., & Bucher, H. C. (2006). Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors: a meta-analysis of randomized controlled trials. Arch Intern Med, 166(3), 285–293. https://doi.org/10.1001/archinte.166.3.285
  76. Novo Nordisk and Noom to partner around digital health solutions to help people with obesity lose weight and keep it off. (2019). PR Newswire. https://www.prnewswire.com/in/news-releases/novo-nordisk-and-noom-to-partner-around-digital-health-solutions-to-help-people-with-obesity-lose-weight-and-keep-it-off-811725389.html
  77. Obesity and overweight. (2024). World Health Organization. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
  78. Phillips, A., & Clements, J. N. (2022). Clinical review of subcutaneous semaglutide for obesity. J Clin Pharm Ther, 47(2), 184–193. https://doi.org/10.1111/jcpt.13574
  79. Poirier, P., Giles, T. D., Bray, G. A., Hong, Y., Stern, J. S., Pi-Sunyer, F. X., & Eckel, R. H. (2006). Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. Arterioscler Thromb Vasc Biol, 26(5), 968–976. https://doi.org/10.1161/01.ATV.0000216787.85457.f3
  80. Prescription Medications to Treat Overweight & Obesity. National Institute of Diabetes and Digestive and Kidney Diseases. https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity
  81. Prescription weight-loss drugs: Can they help you? (2022). Mayo Clinic. https://www.mayoclinic.org/healthy-lifestyle/weight-loss/in-depth/weight-loss-drugs/art-20044832
  82. Roomy, M. A., Hussain, K., Behbehani, H. M., Abu-Farha, J., Al-Harris, R., et al. (2024). Therapeutic advances in obesity management: an overview of the therapeutic interventions. Front Endocrinol (Lausanne), 15, 1364503. https://doi.org/10.3389/fendo.2024.1364503
  83. Rubino, F., Nathan, D. M., Eckel, R. H., Schauer, P. R., Alberti, K. G., et al. (2016). Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations. Surg Obes Relat Dis, 12(6), 1144–1162. https://doi.org/10.1016/j.soard.2016.05.018
  84. Sevan. (2024). The Role of User-Generated Content In Social Media Marketing. https://mind-laboratory.com/user-generated-content/
  85. Singh, G., Krauthamer, M., & Bjalme-Evans, M. (2022). Wegovy (semaglutide): a new weight loss drug for chronic weight management. J Investig Med, 70(1), 5–13. https://doi.org/10.1136/jim-2021-001952
  86. Sjostrom, L., Narbro, K., Sjostrom, C. D., Karason, K., Larsson, B., et al. (2007). Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med, 357(8), 741–752. https://doi.org/10.1056/NEJMoa066254
  87. The startups we back grow fast. (2024). Primary. https://jobs.primary.vc/companies/noom/jobs/38008044-staff-data-scientist
  88. Swift, D. L., Johannsen, N. M., Lavie, C. J., Earnest, C. P., & Church, T. S. (2014). The role of exercise and physical activity in weight loss and maintenance. Prog Cardiovasc Dis, 56(4), 441–447. https://doi.org/10.1016/j.pcad.2013.09.012
  89. Thau, B. (2021). How Noom Tapped Psychology and Technology to Build a $400 Million Weight-Loss App. U.S. Chamber of Commerce. https://www.uschamber.com/co/good-company/the-leap/noom-weight-loss-app-technology
  90. Thorgeirsson, T., Torfadottir, J. E., Egilsson, E., Oddsson, S., Gunnarsdottir, T., et al. (2022). Randomized Trial for Weight Loss Using a Digital Therapeutic Application. J Diabetes Sci Technol, 16(5), 1150–1158. https://doi.org/10.1177/19322968211000815
  91. Timid approach to weight-loss drug fails obesity test. (2023). The Times UK. https://www.thetimes.co.uk/article/timid-approach-to-weight-loss-drug-fails-obesity-test-swlvxxrg5
  92. Tornatzky, L. G., Fleischer, M., & Chakrabarti, A. K. (1990). The processes of technological innovation. Lexington Books.
  93. Tresca, A. J. (2024). 7 Surgical Weight-Loss Procedures: Choosing the Type for You. Verywell Health. https://www.verywellhealth.com/types-of-weight-loss-surgery-8667568
  94. Turnbaugh, P. J., Ley, R. E., Mahowald, M. A., Magrini, V., Mardis, E. R., & Gordon, J. I. (2006). An obesity-associated gut microbiome with increased capacity for energy harvest. Nature, 444(7122), 1027–1031. https://doi.org/10.1038/nature05414
  95. Villar, R. (2024). Digital Health Strategies & Tools for Sustained Weight Loss & Management. Calcium. https://calciumhealth.com/digital-health-strategies-tools-for-sustained-weight-loss-management/
  96. Wadden, T. A., Bailey, T. S., Billings, L. K., Davies, M., Frias, J. P., et al. (2021). Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA, 325(14), 1403–1413. https://doi.org/10.1001/jama.2021.1831
  97. Wadden, T. A., Butryn, M. L., & Byrne, K. J. (2004). Efficacy of lifestyle modification for long-term weight control. Obes Res, 12 Suppl, 151S–162S. https://doi.org/10.1038/oby.2004.282
  98. Wadden, T. A., Butryn, M. L., Hong, P. S., & Tsai, A. G. (2014). Behavioral treatment of obesity in patients encountered in primary care settings: a systematic review. JAMA, 312(17), 1779–1791. https://doi.org/10.1001/jama.2014.14173
  99. Watanabe, K., Wilmanski, T., Diener, C., Earls, J. C., Zimmer, A., et al. (2023). Multiomic signatures of body mass index identify heterogeneous health phenotypes and responses to a lifestyle intervention. Nat Med, 29(4), 996–1008. https://doi.org/10.1038/s41591-023-02248-0
  100. Wearable Tech in Healthcare: Revolutionizing Patient Care. (2024). KMS Healthcare. https://kms-healthcare.com/blog/wearable-technology-in-healthcare/
  101. Wegovy semaglutide. European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/wegovy
  102. Weight-loss platform Noom bulks up on $540 million in new funding. (2021). TechCrunch. https://techcrunch.com/2021/05/25/weight-loss-platform-noom-bulks-up-on-540-million-in-new-funding/
  103. What Is the Noom Diet? What to Know About Noom Weight, Plus Its Cost. (2022). Good Housekeeping. https://www.goodhousekeeping.com/health/diet-nutrition/a26023584/noom-diet-plan-review/
  104. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
  105. Willson, A. (2024). Does United Healthcare cover Wegovy for weight loss? Ro. https://ro.co/weight-loss/does-united-healthcare-cover-wegovy/
  106. Woldemariam, S., Dorner, T. E., Wiesinger, T., & Stein, K. V. (2023). Multi-omics approaches for precision obesity management: Potentials and limitations of omics in precision prevention, treatment and risk reduction of obesity. Wien Klin Wochenschr, 135(5–6), 113–124. https://doi.org/10.1007/s00508-022-02146-4
  107. World Obesity Atlas 2023. (2023). World Obesity Federation. https://www.worldobesityday.org/assets/downloads/World_Obesity_Atlas_2023_Report.pdf
Keywords
Obesity Management AI-Driven Digital Health GLP-1 Receptor Agonists Pharmacotherapy TOE Framework Digital Behavioral Coaching Semaglutide Noom Novo Nordisk Precision Medicine Sustainable Healthcare Solutions Wearable Technology Supply Chain Management
Details
Section Articles
Issue Vol. 2 No. 4 (2026): Volume 2 Issue 4 (April 2026)
Published 2026-04-30
Authors
Kang, Eun Kyoung
EMBA, Aalto/aSSIST University
Kim, Bo Young Primary Contact Corresponding Author
aSSIST University
License
How to Cite
Transforming Obesity Management: Integrating AI-Driven Digital Health and Novel Pharmacotherapy. (2026). ASSIST Business Review, 2(4). https://jnl.ampla.page/abr/article/view/64